81 filings
Page 2 of 5
NT 10-Q
wn50igsv9fcaqwo acb
14 Aug 23
Notice of late quarterly filing
4:36pm
425
8gscy9
11 Aug 23
Business combination disclosure
5:26pm
8-K
x34gos16vvxpu2
11 Aug 23
Entry into a Material Definitive Agreement
5:24pm
8-K
vwh vllb1ntm4rqmadn1
1 Aug 23
Amendments to Articles of Incorporation or Bylaws
5:11pm
DEFA14A
vxyropksfeutx
25 Jul 23
Additional proxy soliciting materials
5:17pm
8-K
83edkvuuy9mho
25 Jul 23
Entry into a Material Definitive Agreement
5:17pm
DEFA14A
nyi9xb ospxzsuzutr
25 Jul 23
Additional proxy soliciting materials
6:08am
8-K
rexyn
25 Jul 23
Entry into a Material Definitive Agreement
6:06am
DEFA14A
v1e3yy seefaxutk2pq0
21 Jul 23
Additional proxy soliciting materials
4:22pm
8-K
a3f8bs2mykh
21 Jul 23
Unregistered Sales of Equity Securities
4:21pm
425
akmc21 sf4v
10 Jul 23
Business combination disclosure
7:13am
8-K
by2ku 8xc
10 Jul 23
Starton Therapeutics Contracts Global Clinical Research Organization to Conduct STAR-LLD Phase 1b Clinical Trial in Multiple Myeloma
7:10am
DEF 14A
209n2nib4mjsfmkab
3 Jul 23
Definitive proxy
9:17pm
8-K
xufgdzi ftuj
29 Jun 23
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
4:05pm
PRE 14A
n5zuje
23 Jun 23
Preliminary proxy
5:19pm
425
xw4ooh4xqtb7r
13 Jun 23
Business combination disclosure
7:05am
8-K
espvt qnel7
13 Jun 23
Regulation FD Disclosure
7:01am
425
ph82diam mlrt4
12 Jun 23
Business combination disclosure
4:44pm
8-K
bnu22tia fdjxmm
12 Jun 23
Starton Therapeutics Receives Authorization from the FDA to Proceed with STAR-LLD Lenalidomide Phase 1b Clinical Trial in Multiple Myeloma
4:42pm